Bayer recently announced that it is embarking on a comprehensive restructuring plan with significant staff reductions.
The Germany-based pharma giant’s management aims to enhance operational performance through a new model called “Dynamic Shared Ownership” (DSO). This strategic change aims to reduce hierarchies, eliminate bureaucracy, streamline structures, and accelerate decision-making processes.
The new model, however, will come at the expense of the jobs of many managerial employees. The layoffs will take place in a decentralized manner through 2025, which means that Bayer cannot initially quantify the size. Bayer has committed to no compulsory redundancies until the end of 2026.
As of the end of 2022, Bayer had more than 101,000 employees, with about a fifth in Germany.
Bayer’s CEO Bill Anderson, who took the helm in June 2023, has emphasized a focus on internal reorganization. This approach delays any break-up plans …